Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $825
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal has maintained an Overweight rating on Eli Lilly (LLY) and increased the price target from $700 to $825.

February 07, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo has maintained an Overweight rating on Eli Lilly and raised the price target from $700 to $825.
The increase in price target by a reputable analyst like Mohit Bansal from Wells Fargo is a strong positive signal for Eli Lilly. It suggests a bullish outlook on the stock's future performance, likely due to anticipated growth, upcoming product launches, or strong financial health. This kind of endorsement can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100